modelFluvastatin
Extends from Pharmacolibrary.Drugs.ATC.C.C10AA04.
Information
| name: | Fluvastatin | |
| ATC code: | C10AA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 40 | mg |
| volume of distribution: | 35 | L |
| clearance: | 1.8 | L/h |
| other parameters in model implementation | ||
Fluvastatin is an orally administered lipid-lowering agent that belongs to the statin class of drugs. It is primarily used to reduce levels of cholesterol and triglycerides in the blood and is approved for the treatment of hypercholesterolemia and mixed dyslipidemia to prevent cardiovascular disease.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose administration.
References
Xu, HR, et al., & Zhu, JR (2012). The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. Journal of biomedicine & biotechnology 2012 386230–None. DOI:10.1155/2012/386230 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22811596
Kirchheiner, J, & Brockmöller, J (2005). Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical pharmacology and therapeutics 77(1) 1–16. DOI:10.1016/j.clpt.2004.08.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15637526
Pincus, KJ, & Hynicka, LM (2013). Prophylaxis of thromboembolic events in patients with nephrotic syndrome. The Annals of pharmacotherapy 47(5) 725–734. DOI:10.1345/aph.1R530 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23613095
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)